Evofosfamide

艾伏磷酰胺

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameEvofosfamide
Drug Alias Name依磷酰胺evofosfamidaevofosfamidumTH-302HAP-302 +[7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursHypoxia +[28
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[19
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesThreshold
China Registration ClassN/A

Develop Information

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsPancreatic Neoplasms +[4
Inactive IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursHypoxia +[24

Other Information

ATC CodeN/A